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NLSBy definition, cytosolic aminoacyl-tRNA synthetases (aaRSs) should be restricted to the cytosol of eukary-
otic cells where they supply translating ribosomes with their aminoacyl-tRNA substrates. However, it has
been shown that other translationally-active compartments like mitochondria and plastids can simulta-
neously contain the cytosolic aaRS and its corresponding organellar ortholog suggesting that both forms
do not share the same organellar function. In addition, a fair number of cytosolic aaRSs have also been
found in the nucleus of cells from several species. Hence, these supposedly cytosolic-restricted enzymes
have instead the potential to be multi-localized. As expected, in all examples that were studied so far,
when the cytosolic aaRS is imported inside an organelle that already contains its bona fide corresponding
organellar-restricted aaRSs, the cytosolic form was proven to exert a nonconventional and essential func-
tion. Some of these essential functions include regulating homeostasis and protecting against various
stresses. It thus becomes critical to assess meticulously the subcellular localization of each of these
cytosolic aaRSs to unravel their additional roles. With this objective in mind, we provide here a review
on what is currently known about cytosolic aaRSs multi-compartmentalization and we describe all com-
monly used protocols and procedures for identifying the compartments in which cytosolic aaRSs relocal-
ize in yeast and human cells.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
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Aminoacyl-tRNA synthetases (aaRSs) constitute a family of
ubiquitous enzymes present in the three kingdoms of life and
essentially known for transfer RNA (tRNA) aminoacylation. Indeed,
they are required for the ligation of the 20 standard proteinogenic
amino acids (aa) to their cognate tRNAs [1]. tRNA aminoacylation
and protein synthesis occur in the cytosol of all organisms but
unlike bacteria, eukaryotes have membrane-enclosed structures
compartmentalizing their cytosol. Among these compartments,
mitochondria in all eukaryotes and also chloroplasts in plants syn-
thesize proteins by translating organellar mRNAs [2]. Hence, a
compartmentalized set of the 20 aaRSs is expected in each
translationally-active compartment. Since no gene encoding mito-
chondrial aaRSs was found in any of the mitochondrial DNA
sequenced so far, the nuclear genome has to encode both full sets
of cytosolic and organellar aaRSs. However, while this is true for
the set of 20 cytosolic aaRSs, a full set of 20 additional separate
genes encoding organellar aaRSs has never been found in any of
the nuclear genomes sequenced so far [3–5]. Both sets of genes
can usually be easily distinguished based on phylogenetic analyses.
These studies show that a majority of the mitochondrial aaRSs are
of bacterial descent but that the a-proteobacterial endosymbiotic
origin of the mitochondrial aaRSs has largely been lost because
of gene replacements, intranuclear gene duplications and diver-
gence or horizontal gene transfers [6,7].
In plants, the evolution of the different aaRSs seems more com-
plicated. Monocot and dicot have either at least 1 gene encoding a
given aaRS for each protein-synthesizing compartment or 2 genes
with one gene encoding the cytosolic and the second both the
mitochondrial and the chloroplastic aaRS [8]. Surprisingly, both
have one instance where only one gene seems to encode all 3 activ-
ities: isoleucyl-tRNA synthetase (IleRS) for monocot and
glutaminyl-tRNA synthetase (GlnRS) for dicot [5,8,9]. The same is
true for diatoms and brown algae in which a single gene seems
to encode all 3 arginyl-tRNA synthetases (ArgRSs) [5]. In many
instances, the mechanism that allows expression of the organellar
aaRS from a gene that also encodes the cytosolic isoform is
unknown or ill defined [10,11]. For the sake of brevity, from now
on we will use the three letters code for each amino acid
mentioned.
Genes encoding several mitochondrial aaRSs are also missing in
metazoan and fungal genomes and various strategies are used by
these organisms to produce the mitochondrial aaRS from an appar-
ently missing gene. Many of them are encoded by the same exact
gene that encodes the cytosolic form, except that the mRNA thatwill be translated into the mitochondrial isoform contains an addi-
tional 50-extension for the mitochondrial targeting sequence
(MTS). The synthesis of these 2 proteins from the same gene is
achieved through different mechanisms: (i) alternative transcrip-
tion start as shown for the yeast ValRS and HisRS mRNAs
[12,13]; (ii) alternative splicing as shown for example for the
human LysRS [14]; (iii) alternative translation initiation at two dif-
ferent AUG start codons within the same mRNA such as for the
human GlyRS [15]; or (iv) alternative transcription start at a non-
canonical start codon such as for the yeast AlaRS [16]. The com-
plete list of cytosolic and organellar aaRSs generated from a single
gene is presented in Table 1.
Eukaryotes, with the exception of a few parasites that possess a
mitochondrial GlnRS encoded by the same gene as the cytosolic
GlnRS, use a different strategy to compensate for the ubiquitous
absence of the gene encoding mitochondrial GlnRS [41]. This wide-
spread absence of a mitochondrial GlnRS is an illustration of the
evolutionary origin of mitochondria that very likely originated
from an a-proteobacterial endosymbiont that was generating
glutaminyl-tRNAGln (Gln-tRNAGln) not by direct charging of tRNAGln
by a GlnRS but by a tRNA-dependent transamidation pathway,
metazoans and fungi kept the endosymbiont’s route for mitochondrial
Gln-tRNAGln formation [42]. This tRNA-dependent transamidation
pathway requires first glutamylation of mitochondrially-encoded
tRNAGln (mttRNAGln) by a mitochondrial non-discriminating GluRS
and subsequent transamidation of the charged glutamate into glu-
tamine by a mitochondrial tRNA-dependent amidotransferase
(AdT) [9,28,43,44]. However, the two enzymes that sustain this
pathway seem to have species-specific features. In human cells,
it is the mitochondrial GluRS that charges both the mttRNAGlu and
the mttRNAGln [44], whereas in the yeast Saccharomyces cerevisiae
a pool of the cytosolic GluRS is imported into the mitochondria
to carry out glutamylation of mttRNAGln [28]. Even if metazoans
and fungi both belong to the opisthokonta group, their trimeric
mitochondrial AdTs differ by one subunit, the classical bacterial-
like GatC subunit found in metazoan AdTs is replaced by a fungi-
specific GatF subunit [45].
In yeast, there is only one CysRS gene (Supp. Table 1) suggesting
that it encodes both the cytosolic and mitochondrial isoforms.
However, the mitochondrial CysRS has yet not been experimen-
tally characterized. Along the same line, S. cerevisiae genome has
two genes, AIM10 and YHR020W that encode for proteins showing
similarities to prokaryotic (AIM10) and eukaryotic (YHR020W)
ProRSs (Supp. Table 1). While there are no experimental proofs that
AIM10 encodes a protein with ProRS activity, its deletion leads to
a respiratory-deficient yeast cell showing that it required for
Table 1
List of dual-localized cytosolic aaRSs identified so far.
Organism Localisation aaRS Techniques used Mechanism References
Hs Mitochondrial GlyRS IF, CF Alternative transcription start [15,17]
LysRS FM Alternative mRNA splicing [14]
Nuclear LysRS CM, CF, CE Phosphorylation [18,19]
MetRS FM, CE, IF, CF Cell growth signal induced [19,20]
PheRS IF n.d. [21]
TrpRS CF, IF, IEM IFN gamma induced [22–24]
TyrRS IF, CM, CF tRNATyr binding [25]
TyrRS CF, IF Oxidative stress induced [26]
Sc Mitochondrial AlaRS G, CF Non-AUG alternative translation start [16,27]
GluRS FM, G, CF, CM Arc1p released [28,29]
GlyRS1 G Non-AUG alternative translation start [30,31]
HisRS G, CF Alternative transcription start [12,32]
ValRS G Alternative translation start [13,33]
Nuclear MetRS FM, CF, CM Arc1p released [29,34]
TyrRS FM, CF NLS characterisation [25,35]
Tb Mitochondrial IleRS IF, CF Trans-splicing [36,37]
GluRS IF, CF Trans-splicing [37,38]
GlnRS IF, CF Trans-splicing [37,38]
ProRS IF Trans-splicing [37]
Pf Apicoplast AlaRS IF n.d. [39]
CysRS FM, IF Alternative mRNA splicing [40]
GlyRS IF n.d. [39]
ThrRS IF n.d. [39]
aaRSs in bold are enzymes that relocalize stricto sensu from cytosol to the organellar compartment. Hs, Homo sapiens; Sc, Saccharomyces cerevisiae; Tb, Trypanosoma brucei; Pf,
Plasmodium falciparum; CM, confocal microscopy; IF, immunofluorescence; CF, cell fractionation; FM, epifluorescence microscopy; CE, capillary electrophoresis; IEM,
immuno-electron microscopy; G, genetic; NLS, nuclear localization signal; n.d., not determined.
S. Debard et al. /Methods 113 (2017) 91–104 93mitochondria function [46]. The protein encoded by the YHR020W
gene has been shown to retain ProRS activity, in vitro, and to be
essential for cell survival, suggesting that it might be the cytosolicFig. 1. Mitochondrial localization of cytosolic and mitochondrial aaRSs. (A) Schematized
that described by Meisinger and coworkers [48]. Mitochondria are recovered from the 60%
yeast mitochondria were subjected to LC MS/MS analysis with 3 different injection grad
proteins identified in each samples are represented in bold. Proteins found shared betwe
of aaRSs identified in mitochondrial extract by LC MS/MS analysis. Colors are correspon
predictor (see Table 5) are in bold. Yeast cytosolic aaRSs previously shown experimenta
specific CysRS identify in yeast. ⁄ indicates putative aaRSs. See Supplemental Table 1 foProRS [47]. The mitoproteome done on purified S. cerevisiae mito-
chondria (performed as described in Section 5; Fig. 1A) shows that
cytosolic CysRS is found in the mitoproteome, suggesting that therepresentation of yeast mitochondria preparation. The procedure we followed was
-32% interphase. (B) LC MS/MS analysis of the mitoproteome. After separation, pure
ients (90 min, 120 min and 90 min Frac, see Section 5 for details). Number of total
en conditions are also showed. (C) Mitochondrial (top) and cytosolic (bottom) forms
ding to samples in panel B. Cytosolic aaRSs predicted to have an MTS by at least 1
lly as mitochondria dual-localized are underlined (see Table 1). No mitochondrial
r yeast aaRSs genes name.
94 S. Debard et al. /Methods 113 (2017) 91–104missing mitochondrial CysRS could be compensated by mitochon-
drial import of the cytosolic ortholog (Fig. 1C). The AIM10 gene pro-
duct was found in the different mass-spectrometry analyses
(Fig. 1C and Supp. Table 2), confirming its mitochondrial localiza-
tion, but further experimental proofs that this protein is a func-
tional ProRS are still needed. Interestingly, the YHR020W gene
product was also found in one of the mass-spectrometry data set
we obtained (Fig. 1C and Supp. Table 2), suggesting that the cytoso-
lic ProRS might be dual-localized. In addition, depending on the
sample injection time used prior to mass spectrometry, 6–8 addi-
tional other cytosolic aaRSs were found in the mitoproteome.
Interestingly, each of these mitochondria-imported cytosolic aaRSs
has a mitochondrial ortholog encoded by a separate gene.
Nonetheless, the deletion of any of these genes encoding the bona
fidemitochondrial aaRS leads to a respiratory deficiency (SGD web-
site source). This means that the cytosolic aaRS orthologs,
imported into mitochondria, cannot compensate for the loss of
the mitochondrial ones and thus suggests that they have other
roles than cognate mttRNA aminoacylation.
Relocalization of cytosolic aaRSs is not restricted to compart-
ments in which their presence is required to supply protein syn-
thesis with aa-tRNAs. Indeed, some cytosolic aaRSs have been
localized in the nucleus both in human and S. cerevisiae (Table 1).
These and other proteins of the translation machinery were first
observed while analyzing the protein content of Xenopus oocytes
and has since also been observed in mammalian and yeast cells
[20,29,49–51]. Their proposed function in the nucleus is that by
charging only the mature tRNAs, these aaRSs are in charge of a
quality-control step of the tRNA maturation process prior to their
export to the cytoplasm [49,50]. More recent reports show other
functions for these nuclear pools of human and yeast aaRSs that
do not require their tRNA-charging capacities. For example, under
oxidative stress a portion of the human TyrRS relocalizes to the
nucleus where it activates E2F1, a transcription factor that up-
regulates the expression of DNA damage repair genes [26]. Like-
wise, a pool of the human MetRS relocalizes into the nucleoli ofFig. 2. Different strategies commonly used for localizing aaRSs in yeast cells. All techproliferating cells to regulate rRNA biogenesis [20]. In the yeast S.
cerevisiae, a pool of MetRS relocalizes into the nucleus to regulate
transcription of genes encoding subunits of respiratory complexes
[29]. More broadly, a previous bioinformatics analysis identified 16
yeast cytosolic aaRSs as harboring a putative nuclear localization
signal (NLS) suggesting that these enzymes could enter the nucleus
to ensure additional functions other than translation [52]. However
the MetRS, experimentally shown to relocalize into the nucleus
was not identified by this bioinformatics study. This highlights
the limits of the bioinformatics prediction algorithms to identify
targeting sequences, hence the difficulties to predict in which addi-
tional compartments these aaRSs could eventually relocalize. How-
ever, the scientific community that studies these enzymes has
come to the consensus that any cytosolic aaRSs could potentially
be multi-localized.
Defining what we mean by multi-localized aaRSs is not an easy
task given the variety of strategies that organisms use to relocalize
the same protein in several compartments. In the present review,
we will define a multi-localized aaRS as a cytosolic aaRS that is
found in at least 2 different compartments and for which the
organellar isoform is produced from the same gene as the cytosolic
one through the various strategies that have been detailed in the
previous paragraphs (see also Table 1).
The mechanisms regulating these multi-localizations have been
mostly studied for aaRSs that belong to multi-synthetase com-
plexes (MSCs) found in all eukaryotic species studied so far. They
are composed of 2–9 cytosolic aaRSs interacting with 1–3 cytosolic
anchors called aminoacyl-tRNA synthetase-interacting multifunc-
tional proteins (AIMPs) [53–59]. It has been proposed and experi-
mentally verified for some of the MSC-interacting cytosolic aaRSs
that these MSCs are reservoirs for releasable aaRSs that can relocal-
ize to other subcellular compartments to exert nonconventional
functions [29,60,61].
In this review, we gather the various methods and procedures
that have been used to address the localization of individual cytoso-
lic aaRSs (Fig. 2). Some are biochemical (organelle purification),niques can be used on mammalian cells except those specific to yeast genetics.
S. Debard et al. /Methods 113 (2017) 91–104 95genetic (isolation of mutations preventing mitochondrial import,
not described in this review) and others are from cell biology
(immunofluorescence on fixed cells or GFP-tagged proteins on liv-
ing cells). The localization of each aaRS in various organisms
together with the techniques that were used to localize them are
described in Table 1. We also mention the predicted organellar
import signals (MTS and NLS) that we found in yeast and human
aaRSs. All the methods described in this review have their advan-
tages and drawbacks, and the purpose of this review is to help
researchers defining which techniques or procedures should be
used to localize a given cytosolic aaRSs. We have focused mainly
on techniques used on yeast and human cells although we mention
work done on other organisms.2. Antibodies: A fundamental tool for aaRSs localization
To ascertain the hitherto unreported localization of pools of
cytosolic aaRSs pool in a compartment can be done by various
methods, but immunodetection will be almost inevitable. Apart
from genetics and tagging one’s favorite aaRS with a fluorescent
protein, all techniques rely on the use of antibodies because of
their high degree of specificity and sensitivity. The key step in con-
firming the localization of a cytosolic aaRS in a compartment with
accuracy and reproducibility is to choose the specific antibodies
against the marker protein of the compartment of interest. TheTable 2
Proteins used as controls for compartment staining and for confirming organellar localiza
Compartment Application Organism
Cytosol WB Hs
Sc
Tb
Nucleus WB Hs
Sc
Nucleolus IF Hs
Mitochondria WB Sc
IF Tb
Apicoplast IF Pf
WB, western blot; IF, immunofluorescence; Hs, Homo sapiens; Sc, Saccharomyces cerev
commercially available; h., homemade.
Table 3
Antibodies used for localizing untagged aaRSs.
Organism Application aaRS Antibody
Hs IF ArgRS h.: rabbit
Glu-ProRS h.: rabbit
GlnRS h.: rabbit
LysRS c.a.; rabbit
MetRS h.: rabbit
PheRS h.; rabbit
TyrRS h.: rabbit
WB TyrRS h.: rabbit
TrpRS h.: rabbit
Sc WB GluRS c.a.; rabbit
HisRS h.; mouse
MetRS c.a.; rabbit
PF WB, IF CysRS h.; rabbit
WB, Western Blot; IF, Immunofluorescence; Hs, Homo sapiens; Sc, Saccharomyces cerevis
homemade.number of antibodies currently available has expanded in the last
years, however published articles often do not report critical
parameters (such as the origin of antibodies, the immunogen used
to raise the antibodies. . .), which sometimes compromises the
reproducibility of the results. Hence there is a push to require for
at least, minimal reporting standards about the use of antibodies
[62,63]. In Table 2, we provide an exhaustive list of proteins that
were used as compartment markers for both immunofluorescence
and Western blot, in studies that report the subcellular localization
of an aaRS. More controls used for yeast cells can be found in the
Current Protocols in Cell Biology paper by Rieder and Emr [64].
Immunodetection of aaRSs, like for any other protein, has so far
been done on either native and unmodified aaRS or on tagged
enzymes. Table 3 lists the few antibodies that were raised against
native aaRSs and that have been used to determine their subcellu-
lar localizations. Since antibodies directed against native aaRSs can
unpredictably cross-react with other proteins and be less sensitive
than expected, most of the immunodetections of aaRSs where per-
formed on tagged-proteins using anti-tag antibodies that usually
are highly specific and sensitive. The main limit of this approach
is that adding a tag at one extremity of the aaRS can potentially
influence the intracellular localization of the chimeric enzyme
[65]. Table 4 lists all the tags that have been fused so far to specific
aaRSs of different organisms, which extremity of the protein was
tagged, which antibody and what approach were used to detect
the tagged aaRSs.tion of aaRSs.
Protein Antibody source References
Tubulin beta n.a. [18]
Hsp90 alpha c.a. [20]
Pgk1 c.a. [29]
Gut2 c.a. [32]
eEF1A n.a. [36]
Lamin B1 c.a. [18,20]
YY1 c.a. [20]
Hta2 c.a. [29]
Nop1 c.a. [29]
Nucleolin c.a. [20]
Por1 c.a. [29]
Atp2 n.a. [32]
Rip1 n.a. [32]
Cit1 n.a. [32]
mHSP70 n.a. [36,37]
ACP h. [39,40]
isiae; Tb, Trypanosoma brucei; Pf, Plasmodium falciparum; n.a., not available; c.a.,
aaRS antigen References
His-tagged 72 N-terminal residues of HsArgRS [20]
His-tagged peptide from D677 to E884 of HsEPRS [20]
His-tagged 236 N-terminal residues of HsGlnRS [20]
n.d [18]
Full-length denatured His-tagged HsMetRS [20]
Endogenous PheRS from sheep liver [21]
n.d [25,26]
n.d [25,26]
Full-length HsTrpRS [22]
His-tagged full-length ScGluRS [29]
Full-length ScHisRS [32]
His-tagged full-length ScMetRS [29]
KLH conjugate 14 C-terminal residues of PfCysRS [40]
iae; Pf, Plasmodium falciparum; n.d., not described; c.a., commercially available; h.,
Table 4
Protein-tags used for localizing aaRSs.
Organism Tag Tagged aaRS Tag position Application Antibody References
Hs GFP ArgRS C-ter CM [66]
AsnRS C-ter CM [66]
LysRS C-ter; N-ter CM, FM [19,66]
MetRS C-ter; N-ter CM, FM [19,66]
V5 epitope GlyRS C-ter IF, WB c.a. [15]
Sc GFP MetRS C-ter; N-ter FM, CM [29,34]
Nter-GluRS C-ter CM [28]
GluRS N-ter FM, CM [34]
TyrRS C-ter FM [35]
V5 epitope GlnRS C-ter WB, FM c.a. [67]
6 His AlaRS C-ter WB c.a. [27]
c-Myc TyrRS C-ter WB c.a. [35]
Tb V5 epitope CysRS C-ter IF c.a. [37]
GluRS C-ter IF c.a. [37]
GlyRS C-ter IF c.a. [37]
IleRS C-ter IF c.a. [37]
MetRS C-ter IF c.a. [37]
ProRS C-ter IF c.a. [37]
SerRS C-ter IF c.a. [37]
ValRS C-ter IF c.a. [37]
3 HA IleRS C-ter IF, WB n.d. [36]
Pf GFP AlaRS C-ter IF, WB c.a. [39]
CysRS C-ter IF, WB c.a. [40]
GlyRS C-ter IF, WB c.a. [40]
ThrRS C-ter IF, WB c.a. [39]
3 HA AlaRS C-ter IF, WB c.a. [39]
GlyRS C-ter IF, WB c.a. [39]
ThrRS C-ter IF, WB c.a. [39]
Hs, Homo sapiens; Sc, Saccharomyces cerevisiae; Tb, Trypanosoma brucei; Pf, Plasmodium falciparum; CM, confocal microscopy; FM, fluorescence microscopy; IF, immunoflu-
orescence; WB, western blot; c.a., commercially available; n.d., not described.
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signal
Among the many bioinformatic predictors of protein localiza-
tions, we chose 3 to predict the presence of an MTS and 3 to predict
NLSs [68]. We used these predictors regardless of the organismal
origin of the aaRSs analyzed. Moreover, to gather as much informa-
tion as possible we tried the ‘‘Euk-mPloc2.0” website (http://www.
csbio.sjtu.edu.cn/bioinf/euk-multi-2/) which predicts whether an
aaRS might be localized to the mitochondria, the nucleus, the cyto-
sol or extracellularly without predicting any targeting sequence of
any kind [69].3.1. Mitochondrial targeting sequence prediction
MTS were predicted using TPpred2.0 (http://tppred2.biocomp.
unibo.it/tppred2) [70], TargetP1.1 (http://cbs.dtu.dk/services/Tar-
getP/) [71,72] and MitoFates (http://mitf.cbrc.jp/MitoFates/cgi-
bin/top.cgi) [73]. Query sequences should be given in the FASTA
format, and depending on the MTS predictor, between 1 and 20
sequences can be analyzed at once. These predictors give back a
mitochondrial probability score, the MTS sequence, the putative
cleavage site that follows the MTS and the N-terminal peptide
resulting from the cleavage. Additionally, MitoFates gives the mito-
chondrial processing enzymes responsible for maturation of the
imported proteins. (Supp. Tables 3a and 3b). The MitoFates predic-
tor was used for fungal, metazoan and plant proteins, while Tar-
getP1.1 was used for non-plant organisms with no cut-off and
with cleavage site prediction.
Submitting the yeast cytosolic aaRSs sequences to these predic-
tors resulted in the HisRS having a strong probability of harbouring
an MTS, the Cys-, Glu- and Val-RS a good probability and the Arg-,
Leu- and Thr-RS only a low probability (Table 5). The predictionshave been partially validated since the relocalization of cytosolic
His-, Glu- and Val-RS has been experimentally described (Table 1).
The good probability of CysRS of having an MTS suggests that it is
the cytosolic CysRS that aminoacylates the mitochondrial-encoded
tRNACys since there is no gene encoding a mitochondrial CysRS.
For human aaRSs, only the mitochondrial LysRS and GlyRS are
encoded by the same gene as the cytosolic form. Mitochondrial
LysRS originates from alternative splicing [14], and the mitochon-
drial GlyRS via an alternative start site [15,17]. Analyzing the
remaining human aaRSs by the predictors shows that only the
CysRS might contain an MTS, however, this cytosolic aaRS has
never been described to localize to mitochondria (Table 5).3.2. Nuclear localization signal prediction
To identify NLS, we used NLStradamus (http://www.moseslab.
csb.utoronto.ca/NLStradamus/) [74], SeqNLS (http://mleg.cse.sc.
edu/seqNLS/) [75], and NLS-Mapper (http://nls-mapper.iab.keio.
ac.jp/cgi-bin/NLS_Mapper_form.cgi) [76] predictors. For all predic-
tors, we used default settings. We added a 60 amino-acids N- or C-
terminal cut-off for the predictions by NLS-Mapper since it is the
only one able to predict bipartite NLSs which are usually found
in the 60 first or last amino acids of a sequence. We therefore only
kept bipartite NLSs of aaRSs fitting this criteria This program is bet-
ter suited for prediction purposes since instead of a simple ‘‘nu-
clear or not nuclear” output, it ranks protein localization on a
scale from exclusively nuclear (8–10), partially nuclear (7–8),
dual-localized cytosol-nucleus (3–5) or exclusively cytosolic
(12). Supplemental Tables 3a and 3b list the results obtained with
these 3 predictors for human and yeast aaRSs.
Schimmel andWang, in their first attempt at identifying NLSs in
the 20 yeast cytosolic aaRSs using the programm PSORT II,
showed that Ala-, Gly-, Pro-, Asn-, Asp-, Gln-, Glu-, His-, Ile-,
Leu-, Lys-, Pheb-, Ser-, Tyr- and Val-RS harbor at least one SV40
Table 5
Predictions of mitochondrial targeting and nuclear localization signals among S. cerevisiae and human cytosolic aaRSs.
MTS predictors1 Localization
predictor
Euk-mPloc2.0
NLS predictors2
TPpred2.0 TargetP1.1 MitoFates NLStradamus SeqNLS NLS Mapper
(Monopartite)
NLS Mapper
(Bipartite)
Yeast Human Yeast Human Yeast Human Yeast Human Yeast Human Yeast Human Yeast Human Yeast Human
Class
I
ArgRS n.p. n.p. n.p. n.p. n.p. n.p. C/M C n.p. n.p. n.p. 1 n.p. n.p. 1 1
CysRS 0.771 0.776 n.p. n.p. 0.539 n.p. C C 1 1 1 2 n.p. n.p. 1 4
GluRS 0.896 0357 n.p. C 1 2 n.p. 1
GlnRS n.p. n.p. n.p. n.p. n.p. n.p. C C 1 n.p. 1 2 1 n.p. n.p. 2
IleRS n.p. n.p. n.p. n.p. n.p. n.p. C C 1 n.p. 2 2 1 1 1 2
LeuRS n.p. n.p. 0.538 n.p. n.p. n.p. C C 2 1 2 2 n.p. n.p. 1 2
LysRS n.p. n.p. n.p. n.p. n.p. n.p. C C 1 1 2 1 n.p. n.p. 2 2
MetRS n.p. n.p. n.p. n.p. n.p. n.p. C C n.p. 1 1 1 n.p. 1 1 3
TrpRS n.p. n.p. n.p. n.p. n.p. n.p. C C 1 n.p. 1 1 1 n.p. 1 1
TyrRS n.p. n.p. n.p. n.p. n.p. n.p. C/N C/E 1 n.p. 2 2 1 1 2 2
ValRS 0.871 n.p. n.p. n.p. 0.996 n.p. C/M C 1 1 1 2 n.p. n.p. n.p. 1
Class
II
AlaRS n.p. n.p. n.p. n.p. n.p. n.p. C/M C n.p. n.p. 2 1 n.p. n.p. 1 1
AsnRS n.p. n.p. n.p. n.p. n.p. n.p. C C 1 n.p. 1 1 n.p. 2 1 2
AspRS n.p. n.p. n.p. n.p. n.p. n.p. C C 1 n.p. 2 1 n.p. n.p. 2 1
GlyRS n.p. n.p. n.p. n.p. n.p. n.p. C C n.p. n.p. 1 2 n.p. n.p. n.p. 1
HisRS 0.556 n.p. 0.846 n.p. 0.996 n.p. C/M C/M 1 n.p. 1 n.p. 1 n.p. 3 2
PheRS1 n.p. n.p. n.p. n.p. n.p. n.p. C C n.p. n.p. 1 1 n.p. 1 n.p. 2
PheRS2 n.p. n.p. n.p. n.p. n.p. n.p. C C n.p. n.p. 1 2 1 n.p. 1 2
ProRS n.p. n.p. n.p. C n.p. 2 n.p. n.p.
SerRS n.p. n.p. n.p. n.p. n.p. n.p. C C 1 1 1 2 n.p. 1 1 1
ThrRS n.p. n.p. n.p. n.p. n.p. n.p. C/M C n.p. 1 2 2 1 n.p. 2 3
GluProRS n.p. n.p. n.p. C 1 2 1 1
n.p.: not predicted; for NLS sequence details see Supp. Table 3a.
1 MTS scores are probabilities of the considered protein to have an MTS.
2 NLS scores are numbers of NLS sequences identified in each aaRS protein. C, cytosolic; M, mitochondrial; N, nuclear; E, extracellular.
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found both in our study and by Schimmel and Wang) [49,77].
Using the aforementioned websites, we could classify the yeast
aaRSs in three groups, those with a strongly probability of having
an NLS (Asn-, Asp-, Cys-, Gln-, Glu-, His-, Ile-, Leu-, Lys-, Pheb-,
Ser-, Trp- and Tyr-RS), those likely to have one (Ala-, Met-, Thr-
and Val-RS) and those unlikely to have one (Arg-, Gly-, Phea-
and Pro-RS) (Table 5). We see a high overlap between the pub-
lished results and our own suggesting the robustness of the meth-
ods used. It is noteworthy that the MetRS missing from the original
list was predicted by NLS-Mapper and then by SeqNLS. Despite the
fact that these bioinformatics studies highlight the presence of
NLSs in many cytosolic aaRSs, only 2 have been experimentally
confirmed: the MetRS [29] and the TyrRS (3 bioinformatically
found NLSs and one confirmed [35]). This emphasizes the need
to use different algorithms to identify NLSs and that they are not
yet sufficiently accurate to not require experimental confirmation.
Similar NLS prediction analysis has been done on human cells
(Table 5). Using the aforementioned websites, we could classify
the human aaRSs in three groups, those with a strong probability
of having an NLS (Cys-, GluPro-, Leu-, Lys-, Met-, Pheb-, Ser-,
Thr- and Val-RS), those likely to have one (Ala-, Arg-, Asn-, Asp-,
Gln-, Gly-, Ile-, Phea-, Pheb, Trp- and Tyr-RS) and the ones unlikely
to have an NLS (HisRS).
The fact that NLS predictions for yeast and human aaRSs con-
verge seem to reinforce the hypothesis that this localization is true
and not artifactual. The one notable exception is HisRS which is
most likely nuclear in yeast and most unlikely in human. Since
the nuclear localizations of the MetRS, TyrRS and IleRS have been
determined experimentally, we can speculate that either some of
their functions are shared and would have been present in their
common ancestor, or that they exert different roles suggesting that
the functions were acquired after the opisthokonta splitting
(Table 5).4. Subcellular fractionation
Subcellular fractionation can be divided into 3 different tech-
niques according to the precision of the separation and the orga-
nelle that one wants to purify: crude membranes fractionation,
nuclear purification and mitochondrial purification.
4.1. Crude membranes fractionation from yeast cells
This technique allows the separation of membranes from the
cytosol (S100) and yields 2 separate membrane fractions (P13
and P100). To analyze the subcellular distribution of yeast aaRSs
we performed a subcellular fractionation adapted from the proto-
col published by Bonangelino and collaborators [78].
- Yeast cells are inoculated in the morning or the previous eve-
ning depending on the generation time in the appropriate med-
ium (YPD or SC dropout) on a rotary shaker at 200 rpm at 30 C.
- In the evening, the cells are diluted in 100 mL of the same med-
ium to reach an OD600nm of about 0.5 in the morning. 40 units of
OD600nm are transferred to a 50 mL Falcon tube. From here on
out, all steps are performed on ice and centrifugations are per-
formed at 4 C.
- The cell suspension is centrifuged for 5 min at 5250g at 4 C to
pellet the cells. For cells grown on SC dropout medium, add
1 mL of YPD to facilitate the pelleting.
- Cells are washed twice in 20 mL of ice cold fractionation buffer
(20 mM Hepes/KOH, pH 6.8, 50 mM CH3COOK, 10 mM MgCl2,
250 mM Sorbitol, 10 mM NaN3).
- Cells are then resuspended in 800 lL of fractionation buffer
(with protease inhibitor cocktail cOmplete ULTRA Tablets,
EDTA-free from RocheTM) and transferred into a 15 mL cold Cor-
exII centrifuge tube (ref. 1-8441-15) containing 650 lL of glass
beads (acid washed 0.25–0.5 mm diameter beads).
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- The lysat is transferred to a 1.5 mL microfuge tube and cen-
trifuged at 4 C for 5 min at 500g in a fixed-angle rotor to clarify
it.
- The S5 supernatant is carefully transferred to a fresh microfuge
tube and centrifuged at 4 C for 10 min at 13,000g in a fixed-
angle rotor.
- The pellet (P13), which mainly contains the plasma membrane,
the endoplasmic reticulum, the nucleus, the vacuole and mito-
chondria, is kept on ice until the end of the experiment.
- The supernatant (S13) is transferred in a 1.5 mL ultracentrifuga-
tion microfuge tube (Beckman Coulter ref. 357448) for further
centrifugation at 4 C for 1 h at 100,000g in an ultracentrifuge
using a fixed rotor.
- The supernatant (S100), which contains cytosol and vesicles, is
carefully transferred to a fresh 1.5 mL microfuge tube. The pel-
let (P100) contains Golgi and endosomes.
- P13 and P100 are subsequently resuspended in fractionation
buffer in the same volume as the S100 fraction.
4.2. Purification of nuclei and preparation of nuclear protein extracts
Purification of nuclei needs to be performed quickly to avoid
passive diffusion of small proteins through nuclear pores. More-
over, the composition of buffers is critical for maintaining osmotic
balance to prevent nuclear proteins from leaving the nucleoplasm
fraction.
4.2.1. Purification of nuclei from yeast cells
This method is an adaptation from the original protocol of Ste-
phanie E. Rieder and Scott D. Emr [79].
- Yeast cells from 2 L of culture in rich or synthetic medium,
depending on auxotrophic markers or studied conditions, are
harvested at 0.7 OD600 and washed once with water to ensure
that all traces of medium are eliminated.
- The wet pellet is weighed (approximately 7 g/2 L of culture).
Pellet is resuspended in 100 mM Tris H2SO4, 10 mM DTT in a
volume of 2 mL/g of wet cells and incubated 20 min at 30 C
with gentle agitation. The purpose of this step is to weaken
the cell wall.
- The mixture is centrifuged 4 min at 3500g and the pellet is
washed with 1.1 M sorbitol to keep osmotic pressure, 100 mM
K2HPO4/KH2PO4, pH 7.4 using 7 mL of buffer per g of cells and
resuspended with the same buffer.
- Zymolase 20T is added to the mixture (5 mg/g of pellet) and
incubated during 45 min at 30 C with gentle agitation
(80 rpm), to digest the cell wall.
All following steps are performed at 4 C, to avoid protein
degradation. Approximately 3.5 g of wet cells should be settled
by falcon 50 (two falcons 50 for 2 L of culture at 0.7 OD600nm). Note
that all the subsequent steps are detailed for the treatment of 1 fal-
con 50 out of the two necessary to treat the whole 2 L culture.
- The spheroplasts (cells without their wall) are centrifuged
4 min at 3500g, gently resuspended in 1.1 M sorbitol, 100 mM
K2HPO4/KH2PO4, pH 7.4 to remove the zymolase and cen-
trifuged again 4 min at 3500g.
- The pellet is resuspended in 20 mL 1.1 M sorbitol, 100 mM
K2HPO4/KH2PO4, pH 7.4 and loaded on a 6 mL cushion contain-
ing 30 mM sorbitol, 5% (v/v) ficoll 400, with protease inhibitors.
The spheroplasts are centrifuged 10 min at 4000g.
- The pellet is resuspended into 15 mL of ice cold ficoll 20% (v/v),
20 mM K2HPO4/KH2PO4, pH 7.4, 1 mM MgCl2 and protease
inhibitors, and the spheroplasts are broken by osmotic shockin potter by 20 S in maximum 5 min. The ficoll keeps the osmo-
tic pressure between the medium and the nuclei, to avoid
nuclear protein from diffusing out of the nucleus.
- The lysate is incubated 10 min on ice to let nuclei cool
down prior to subsequent centrifugation during 5 min at
13,000g.
- The supernatant is collected and immediately centrifuged again
10 min at 13,000g. At this step, nuclei cannot pellet because of
the viscosity of the buffer.
- The supernatant is then loaded on a ficoll gradient containing
20 mM K2HPO4/KH2PO4 pH 7.4, 1 mM MgCl2, protease inhibi-
tors and ficoll 50% (v/v), ficoll 40% (v/v), ficoll 30% (v/v), 6.5 g
each in 25  89–mm ultracentrifuge tube (Beckman Coulter,
Ultra Clear Tubes, 38.5 mL, ref. 344058). Then, the gradient is
ultracentrifuged 1 h at 58,000g (Beckman, SW28 rotor,
18,000 rpm).
- After the centrifugation, the 20 and 30% layers containing all the
cellular debris are removed. The 40% layer and the interface 40–
50% containing the nuclei are harvested by pipetting. Nuclei are
also present in the interface 30–40%, but this interface layer is
not harvested because it contains too many non-nuclear
contaminants.
- To remove the ficoll, the samples are diluted 10 times in 20 mM
K2HPO4/KH2PO4, pH 7.4, 1 mMMgCl2 and centrifuged 10 min at
10,000g to pellet nuclei (since the ficoll is diluted, nuclei are
able to pellet at 3000g).
- Nuclei are finally resuspended in 500 lL of buffer containing
100 mM Tris HCl pH 7.8, 0.1 mM EDTA, 5 mM b-
Mercaptoethanol, 1 mM benzamidine, protease inhibitors, and
sonicated for 80 s (1 s on/1 s off, 30% amplitude, Bioblock Vibra-
cell) in order to disrupt the nuclear enveloppe.
- After a chilling step on ice to avoid foaming, nuclei are re-
sonicated for 30 s (1 s on/1 s off, 30% amplitude, Bioblock
Vibracell).
- The nuclear extracts are ultra-centrifuged 30 min at 100,000g to
pellet nuclear membranes. The supernatant contains soluble
nuclear proteins.
4.2.2. Purification of nuclei from human cells
This protocol is adapted from Jason M. Dahlman and Denis C.
Guttridge [80]. Perform all steps at room temperature unless
otherwise specified. Volumes are determined for the preparation
of 10 samples. All centrifugation was performed in a bench top
microfuge. A minimum of 1  106 cultured cells are used for this
protocol.
- Cell culture media is removed from the plates.
- Cells are gently washed twice with 1 mL of PBS (137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4).
- After the addition of 1 mL of PBS, cells are removed from the
polystyrene tissue culture dish using a cell scraper.
- Scraped cells (1 mL) are removed with a 1 mL pipette and
placed in a 1.5 mL microcentrifuge tube.
- Cells are centrifuged at 250g for 5 min at 4 C.
- After centrifugation, supernatants are removed and 5 pellet
volumes of cytoplasmic extraction buffer (CEB: 10 mM HEPES-
KOH, pH 7.6, 60 mM KCl, 1 mM EDTA, 0.25% (v/v) Tergitol-
type NP-40 (Sigma-Aldrich), Complete protease inhibitor
cocktail, EDTA-free (Roche)) are added to each sample.
- Cellular pellets are dissolved by flicking the tubes. It is impor-
tant to minimize the amount of bubbles generated while
flicking. After adding the cytoplasmic extraction buffer, let sam-
ples stand on ice for 1–3 min before resuspending and make
sure that cellular pellets are completely dissolved.
- Resuspended pellets are incubated on ice for 5 min and then,
centrifuged at 650g for 4 min at 4 C.
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proteins, are carefully transferred to new 1.5 mL microcen-
trifuge tubes. While removing the supernatant, take special care
not to disrupt the nuclear pellet, which now should take on
an opaque appearance. The cytoplasmic extract can be either
disposed of or stored at 80 C.
- 100 lL of cytoplasmic wash buffer (CWB: 10 mM HEPES-KOH,
pH 7.6, 60 mM KCl, 1 mM EDTA, Complete protease inhibitor
cocktail, EDTA-free (Roche)) is added to the nuclear pellets to
remove the excess of NP-40. The 1.5 mL microcentrifuge tubes
are gently tapped to dislodge the nuclear pellets. There is no
need to resuspend the pellets.
- Centrifugation is repeated at 650g for 4 min at 4 C.
- Supernatants are carefully discarded, once again taking care not
to disturb the nuclear pellets.
- 1 pellet volume of nuclear extraction buffer (NEB: 20 mM Tris
HCl pH 8.0, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25%
(v/v) glycerol, Complete protease inhibitor cocktail, EDTA-free
(Roche)) is added to the 1.5 mL microcentrifuge tubes contain-
ing the nuclear pellets and they are resuspended by flicking the
tubes until they are completely resuspended. Try to minimize
the amount of bubbles you generate while flicking.
- The resuspended nuclear pellets are incubated on ice for 10 min
and mixed by flicking every 2 min.
- After the 10 min incubation, the resuspended nuclear pellets
are centrifuged at 15,000g for 10 min at 4 C.
- After centrifugation, supernatants, containing the nuclear
proteins, are transferred to new pre-chilled 1.5 mL micro
centrifuge tubes
- Nuclear extracts are stored at 80 C.
4.3. Purification of mitochondria and preparation of mitochondrial
protein extracts
4.3.1. Purification of mitochondria from yeast cells
To analyze the mitochondrial localization of aaRSs, we per-
formed a mitochondria purification (described below) adapted
from the protocol published by Meisinger and collaborators [48].
- All steps are perform at 4 C unless otherwise specified. To get
enough mitochondria it is recommended to use at least 2–3 L
of yeast cells grown to log-phase.
- Yeast cells are pelleted by centrifugation at 3000g for 5 min and
resuspended in distilled water.
- Cells are pelleted again as for nuclei preparation, the wet
weight is measured and the pellet is resuspended at a concen-
tration of 2 mL/g of pellet in prewarmed at 30 C DTT buffer
(100 mM Tris-H2SO4, pH 9.4, 10 mM dithiothreitol (DTT)).
- After 20 min incubation in a 30 C shaker at 80 rpm, cells are
pelleted at 3000g for 5 min and resuspended in 7 mL/g of zymo-
lyase buffer (1.2 M sorbitol, 20 mM potassium phosphate, pH
7.4), pelleted again at 3000g for 5 min and resuspended at a
concentration of 7 mL/g of cells in zymolyase buffer containing
3 mg Zymolyase 20T (Seikagaku Kogyo Co., Tokyo, Japan) per
gram wet weight.
- After incubation for 45 min in 30 C shaker at 80 rpm, cells are
pelleted at 3000g for 5 min and resuspended in 7 mL/g of fresh
zymolyase buffer, pelleted again at 3000g for 5 min and resus-
pended (6.5 mL/g wet weight) in ice-cold homogenization
buffer (0.6 M sorbitol, 10 mM Tris HCl, pH 7.4, 1 mM EDTA,
0.2% (w/v) BSA (Sigma-Aldrich), and 1 mM of freshly prepared
PMSF).
- From this step, it is very important to maintain the lysate,
buffers and rotors at 4 C to prevent proteolysis.
- Samples are poured in a glass Teflon homogenizer and sphero-
plasts are homogenized with 15 S.- Samples are then 2-fold diluted with ice-cold homogenization
buffer and the lysate is cleared by centrifugation at 1500g for
5 min to remove cell debris and nuclei.
- The supernatant is centrifuged at 4000g for 5 min, the pellet is
discarded and the supernatant is centrifuged again at 12,000g
for 15 min to isolate the mitochondrial fraction.
- The supernatant is discarded and the mitochondrial pellet is
resuspended in 0.5 to 1 mL of SEM buffer (250 mM sucrose,
1 mM EDTA, 10 mM MOPS-KOH, pH 7.2) and the protein con-
centration is measured using the Bradford method and adjusted
to 5 mg/mL.
In order to obtain highly purified mitochondria, firstly prepare
sucrose step gradients in Beckman centrifuge tubes (Beckman
Coulter, Ultra Clear Tubes, 13.2 mL, ref. 344059):
- 1.5 mL 60% (w/v) sucrose diluted in EM buffer (1 mM EDTA,
10 mM MOPS-KOH, pH 7.2) is loaded at the bottom of the cen-
trifuge tube.
- Without disturbing the phases, 4 mL 32% (w/v), 1.5 mL 23%
(w/v), and 1.5 mL 15% (w/v) sucrose/EM are carefully pipetted
stepwise and the tubes are kept at 4 C.
- Samples are homogenized again in a glass Teflon homogenizer
(10–15 strokes) and poured (0.2 to 1 mL) to the sucrose
gradient.
- The clarified samples are then centrifuged (Beckman, SW41 Ti
rotor) at 134,000g for 1 h at 4 C and the highly purified mito-
chondria are collected with a Pasteur pipette from the 60–32%
sucrose interface.
- Mitochondrial samples are diluted 2-fold in SEM buffer and
centrifuged at 12,000g for 15 min. Repeat this step to wash
the purified mitochondria.
- Pellet can be frozen at 80 C.
For extraction of soluble mitochondrial proteins, mitochondria
are disrupted by sonication (see below) otherwise they are resus-
pended in SEM buffer and the concentration is adjusted as
required.
- Mitochondria pellets are resuspended in 1 vol of lysis buffer
(50 mM Tris-HCl, pH 7.2, 1.1 M Sorbitol, 2 mM EDTA; 5 mM
b-mercaptoethanol).
- Sonication (4 run of 10 S with a 2 s duration time, amplitude
25%; Vibracell) is performed with a small probe (2 mm
diameter) on ice.
- Broken mitochondria are then centrifuged for one hour at
105,000g at 4 C to eliminate unbroken mitochondria and
disrupted membranes.
- The supernatant which is recovered, corresponds to soluble
mitochondrial proteins and can be frozen at 80 C.
4.3.2. Obtention of mitoplasts from yeast mitochondria
For generation of mitoplasts, digitonin is used to permeabilize
the outer mitochondrial membrane of yeast mitochondria.
- Mitochondria are suspended at a concentration of 1 mg/ml in
SEM buffer.
- 250 lg of mitochondria are incubated for 25 min on ice in
250 ll of SEM buffer containing 0.05% to 0.2% digitonin.
- The resulting mitoplasts are harvested by spinning at
14,000 rpm for 10 min and the supernatant is saved for further
analysis.
- The mitoplast containing pellet is washed once again with SEM
buffer.
- To determine the efficiency of digitonin treatment, 100 lg of
mitochondria are treated as above with digitonin, centrifuged,
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and transferred to a polyvinylidene difluoride membrane
(Immobilon P, Millipore). Immunoblots are performed using
antibodies specific for cytochrome c peroxidase (CCPO)
(intermembrane space), TIM23 (inner membrane), delta-1-
pyrroline-5-carboxylate dehydrogenase (Put2p) (matrix) and
porin (outer membrane).
4.3.3. Purification of mitochondria from human cells
This protocol is adapted from Jason M. Dahlman and Denis C.
Guttridge [80] and has been designed to extract mitochondria from
HeLa cells. Volumes are adapted to cells grown in 5 flasks of 58
cm2. All steps are performed on ice or at 4 C.
- Cell culture growth media from desired cells is removed.
- Cells are gently washed twice with 5 mL of PBS (see
Section 4.2.2).
- Cells are removed from the polystyrene tissue culture dish by
adding 1 mL of PBS and the cells are scraped gently with a cell
scraper.
- Cells are centrifuged for 5 min at 250g at room temperature
- The pellet is resuspended in 1 mL of BSA buffer (0.6 M sorbitol,
1 mM EDTA, 20 mM Hepes-KOH, pH 7.6, 300 mM NaCl, Com-
plete protease inhibitor cocktail, EDTA-free (Roche) and 0.3%
(v/v) of BSA (1 mg/mL)).
- Cells are then mechanically broken on ice by repeated (at least
80 times) aspiration/backflow using a 1 mL syringe with a G23
needle.
- The lysate is centrifuged twice at 1200g for 6 min at 4 C.
- The supernatant is then centrifuged at 16,000g for 40 min at
4 C.
- Pellet can be frozen at 80 C.
4.3.4. Obtention of mitoplasts from human mitochondria
For generation of mitoplasts, digitonin is used to permeabilize
the outer mitochondrial membrane of human mitochondria.
- Mitochondria-containing pellet is resuspended in 300 lL BSA
buffer (0.6 M sorbitol, 1 mM EDTA, 10 mM Hepes-KOH, pH 6.7
and 0.3% (v/v) of BSA (1 mg/mL)) containing 0.2% digitonin
(50 lL of a 1 mg/mL stock solution) and incubated 15 min at
room temperature.
- 1 mL of BSA buffer is added and the mixture is centrifuged
20 min at 16,000g at 4 C.
- The resulting pellet is washed two times with 1 mL BSA buffer
without resuspending the mitoplasts.
- The final mitoplasts-containing pellet can be resuspended in
various types of buffers depending on the subsequent analyses
that will be performed (TRIzol (Invitrogen) for RNA extraction,
Laemmli for SDS-PAGE analysis. . .) or stored at 80 C as a
wet pellet.
5. Mass spectrometry analysis and identification of cytosolic
aaRSs in yeast mitochondrial extracts
We performed yeast mitochondria purification as explained in
the Section 4.3.1 and recovered pure mitochondria at the 32–60%
interphase from a cushions gradient (Fig. 1A). In order to identify
mitochondrial proteins, mitochondria were disrupted (see Section
4.3.1) and soluble proteins were subjected to mass spectrometry
(see protocol below). For analysis, we carried out 3 different injec-
tions, two of 90 min (one regular and one using restricted mass
ranges of 400–800 m/z and 800–1250 m/z, termed Frac.) and one
of 120 min. These features allowed us to identify 905 (90 min.),
982 (90 min. Frac.) and 926 (120. min) mitochondrial proteins
respectively (Fig. 1B). We describe here the detailed procedurefor protein digestion and mass spectrometry analysis as well as
data analysis.
5.1. Protein digestion solution
- Proteins from mitochondrial extracts are resuspended in
50 mM ammonium bicarbonate.
- After a reduction-alkylation step (5 mM DTT and 10 mM
iodoacetamide), proteins are digested overnight with 100 ng
of sequencing-grade trypsin (Promega).
- After centrifugation at 12,000g, the supernatants are collected
in glass inserts and vacuum dried.
5.2. Nano-liquid Chromatography – electrospray Ionization TripleTOF
MS/MS Analysis
- Before injection, dried peptides are resuspended in 15 lL of
0.1% (v/v) formic acid. One third of each sample was injected
on a NanoLC-2DPlus system (nanoFlexChiP module; Eksigent,
ABSciex, Concord, Ontario, Canada) coupled to a TripleTOF
5600 mass spectrometer (ABSciex) operating in positive mode.
- Peptides are loaded with a trap and elute configuration on C18
reverse-phase columns (ChIP C-18 precolumn 300 lm
ID  5 mm ChromXP and ChIP C-18 analytical column 75 lm
ID  15 cm ChromXP; Eksigent).
- Peptides are eluted by using a 5–40% gradient of 0.1% (v/v) for-
mic acid in acetonitrile for 90 or 120 min at a 300 nL/minute
flow rate. The TripleTOF 5600 was operated in high-sensitivity
data-dependant acquisition mode with Analyst software (v1.6,
ABSciex) on a 400–1250 m/z range.
- To extend the sensitivity, two new injections are carried out
using restricted mass ranges, 400–800 m/z and 800–1250 m/z.
An external calibration is performed before each sample by
monitoring 10 peptides of a beta-galactosidase trypsic digest.
A discovery ‘‘Top20” method is used: up to 20 of the most
intense multiply-charged ions (2+ to 5+) are selected for CID
fragmentation, with a cycle time of 3.3 s.
5.3. Database search and data analysis
Raw data are first converted to Mascot Generic File format
(.mgf) and searched against the yeast S. cerevisiae database supple-
mented by a decoy database (reverse sequences). The database
search algorithm used is Mascot (version 2.2, Matrix Science, Lon-
don, UK) through the ProteinScape 3.1 package (Bruker Daltonics,
Leipzig, Germany). Peptide modifications allowed during the
search are: N-acetyl (protein), carbamidomethylation(C) and oxi-
dation (M). Mass tolerances in MS and MS/MS is set to 20 ppm
and 0.5 Da, respectively. Two trypsin missed cleavages sites is
allowed. Peptide identifications obtained from Mascot is validated
with a protein FDR < 1%, using the Protein Assessment tool from
ProteinScape. Identified proteins are assessed by spectral count.
The aaRSs identified in the mitochondrial extract analyzed by
three different injections methods are presented in Fig. 1C and
Supp. Table 2. Excepting the Arg-, Met- and Thr-RS (note that there
are no genes encoding the mitochondrial CysRS and GlnRS in
yeast), we found all the mitochondrial aaRSs in our assay. The
absence of these three mitochondrial aaRSs could be due to a
strong binding to the mitochondrial membrane that resulted in
their loss during the protein extract preparation. Indeed, it has
previously been shown that a functional aaRS could be membrane-
anchored [81]. In addition to the mitochondrial aaRSs, we
identified 10 cytosolic ones (Asp-, Glu-, Ile-, Leu-, Lys-, Phe-, Pro,
Ser-, Thr- and Tyr-RS) of which only the cytosolic GluRS has been
shown experimentally to be dual-localized [28,29]. Since there is
no gene identified for the yeast mitochondrial CysRS, we assume
Table 6
List of markers for specific compartments in mammalian cells and their respective
antibodies.
Compartment Protein marker* Antibody
Nucleus Lamin B1 Abcam ab16048
Plasma membrane Cadherin Abcam ab6528
Endoplasmic Reticulum Calnexin Abcam ab22595
Calreticulin Abcam ab2907
GRP-78 Abcam ab21685
Golgi GM130 Abcam ab31561
Giantin Abcam ab80864
TGN46 Abcam ab2809
Mitochondria COX IV-1 Abcam ab14744
Cytochrome c Abcam ab13575
Endosomes Early endosome antigen 1 Abcam ab2900
Ras related protein Rab-5A Abcam ab18211
Ras related protein Rab-7a Abcam ab126712
Lysosomes LAMP-1 Abcam ab24170
LAMP-2 Abcam ab18529
Autophagosomes MAP1A/MAP1B LC3 A Abcam ab52768
Peroxisomes Catalase Abcam ab16771
* Protein marker names are recommended names or short names from the
UniProt database.
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indeed, found it in the mitochondrial fraction we analyzed. It is
now important to confirm the mitochondrial localization of these
cytosolic aaRSs and then determine their function in this other
compartment.
6. Microscopy analysis and single cell localization
Unlike subcellular fractionation, microscopic analysis allows
the study of aaRSs localization at the single cell scale. For more pre-
cision, a confocal microscope is needed to set only one focal plan
and prevent accumulation of cytosolic fluorescence around the
organelle. If the aaRS is fused to GFP, analysis can be performed
directly on living cells, and aaRSs used with a GFP-tag are listed
in Table 4. To control the aaRS localization on living cells, the need
of compartment markers is essential, like DAPI and Mitotracker for
nuclear and mitochondrial compartment, respectively. For yeast
cells, some additional fluorescent dyes can also be used for fluores-
cent microscopy on living cells, as CellTracker Blue CMAC
(ThermoFischer Scientific, ref. C2110) that is specific for vacuolar
lumen (DAPI filter), or FM4-64 (ThermoFischer Scientific, ref.
T3166) used in time lapse experiments to stain the plasma mem-
brane, the endosomes and the vacuolar membrane (RFP filter)
[82]. For more precision, protein markers can be targeted by speci-
fic antibodies: frequently used markers for mammalian intracellu-
lar compartments are listed in Table 6. As GFP can possibly perturb
the aaRS localization due to its large size, smaller tags (listed in
Table 4) have been used for immunofluorescence (IF) study. For
IF, a fixation step is essential to allow antibodies penetration in
the sample. Next sections present immunofluorescence protocols
for both yeast and human cells.
6.1. Immunofluorescence on yeast cells
This technique allows the observation by fluorescent micro-
scopy of the aaRSs of interest on fixed yeast cells.
6.1.1. Fixation steps
- Cells are grown overnight in 20 mL of either complete or syn-
thetic medium (YPD or SC dropout medium) to about 1  107
cells/mL (OD600nm = 0.4–0.6); 10 mL culture gives 6 samples.
- 1.25 mL of 1 M K2HPO4/KH2PO4, pH 6.5 and 1.25 mL of 37% (v/v)
formaldehyde are added to 10 mL of overnight culture(10  107 cells) and incubated for 2 h at room temperature with
gentle shaking every 30 min.
- Cells are centrifuged for 5 min at 3000g, washed 3 times with
10 mL SP buffer (1.2 M sorbitol, 0.1 M KPO4, pH 6.5) and resus-
pended in 1 mL SP/ME (SP, 20 mM b-mercaptoethanol).
- 10 lL Zymolyase 20T (5 mg/mL) is added and the mixture is
incubated 45 min at 30 C (gentle shacking every 10 min); the
amount of Zymolyase needed depends on the strain.
- Cells are centrifuged for 5 min at 2000g, washed 3 times with
3 mL SP buffer and resuspended in 0.1 mL SP; after the diges-
tion of the cell wall, the resuspension has to be very gentle to
avoid lysis.
- Cells are stored at 4 C (can be kept for 1–2 weeks).
6.1.2. Incubation with antibodies
The following steps are done on a slide for immunofluorescence
(HTC or epoxy, single use slides, diameter 6 mm) at room
temperature.
- Slides are washed with ethanol 96% (v/v).
- 20 lL of poly-Lysine (0.1% (w/v) in H2O) is added to each well
and incubated for 1 min.
- The liquid is removed, slides are dried and washed 3 times with
20 lL H2O; all washing steps are done by adding one drop (with
Pasteur pipette) and removing with vacuum without touching
the slide.
- Slides are placed in a humid chamber (Petri dish with H2O-
soaked paper), 15 lL of fixed yeast cells are added to each well
and incubated for 30 min.
- The excess of liquid is removed very gently and slides are
washed twice with PBS 1 (see Section 4.2.2).
- Slides are then incubated for 5 min with 15 lL of PBT (PBS 1,
Triton X-100 0.1% (v/v), NaN3 0.1% (w/v), BSA 1% (w/v)).
- After removing the excess of liquid, slides are incubated for
30 min at room temperature with 15 lL of primary antibody
diluted in PBT, according to manufacturer indications.
- Slides are washed 10 times with PBT, followed by the incuba-
tion for 30 min in the dark and at room temperature with
15 lL of secondary antibodies (either Cy-conjugated or Alexa
Fluor-conjugated; ThermoFischer Scientific) diluted in PBT.
- Slides are washed 10 times with PBS.
- Optional: Nuclei can be stained with 15 lL of DAPI (10 lg/mL)
and incubated 5 min in the dark. 5 washes with PBS are needed
to avoid non-specific background fluorescence.
- Finally, 3 lL of Vectashield (Vector laboratories) are added and
slides are covered with coverslip; fix coverslip on all ends with
nail polish.
- Slides can be stored at 4 C in the dark (can be kept for months)
or directly observed by fluorescence microscopy.
6.2. Immunofluorescence on human cells
This technique allows observing the subcellular localization of
the aaRSs of interest in fixed mammalian cells on a single cell scale
with a fluorescence microscope.
- Cells are grown in complete medium, mostly DMEM (D5796
Sigma) or MEM (M2279 Sigma), supplemented with 10% (v/v)
Fetal Calf Serum (FCS).
- On day one of the experiment, the medium of the culture flask
is removed, cells are washed with PBS (see Section 4.2.2.) and
detached using trypsin (T4049 Sigma).
- Cells are then spotted on 10-well spotslides (Marienfeld Supe-
rior, #1216650) to a 70% confluency (for most cell types
4000–5000 cells per spot), let to attach and grown overnight
in a cell culture incubator at 37 C, 5% CO2.
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4% (v/v) formaldehyde (F8775 Sigma) in PBS to the spots and
incubated for 20 min at room temperature.
- If Mitotracker (Thermofisher Scientific, M7512) is used to detect
mitochondria, Mitotracker staining has to be done on live cells
prior to fixation. Therefore, cells are incubated for 15–45 min at
37 C with Mitotracker diluted in pre-warmed medium (37 C)
to a concentration of 100–500 nM. Cells are then washed once
in medium and once in PBS and fixed as described above.
- Cells are then washed once with PBS and permeabilized with
0.2% (v/v) Triton-X 100 (Sigma-Aldrich) in PBS for 10 min at
room temperature.
- After one more wash with PBS, unspecific sites are blocked by
incubation with 20% (v/v) FCS in PBS for one hour at RT.
- Cells are then incubated with the antibodies raised against the
aaRS of interest and marker proteins of the different subcellular
compartments in PBS-2% (v/v) FCS for two hours at room
temperature or overnight at 4 C.
- After washing five times with PBS, the fluorophore-conjugated
secondary antibodies diluted in PBS-2% (v/v) FCS are added
for one hour at room temperature. DAPI can be added to the
secondary antibody solution at a concentration of 300 nM.
- Finally, after two final washes in PBS, a drop of pre-warmed
(50 C) elvanol (Poly(vinyl alcohol) – 341584 Sigma-Aldrich) is
added to each spot and the slide sealed with a coverslip. Cells
are then visualized using a confocal laser scanning microscope
and fluorescence can be quantified with the ImageJ software.
7. Concluding remarks
Localizing multi-compartmental aaRSs cannot be done using a
one-for-all technique. For example, using fluorescence microscopy
to simultaneously visualize in a single cell, the organellar and
cytosolic fractions of the same aaRS (or protein in general) is com-
plicated since the fluorescence of the organellar pool will be
masked by the fluorescence of the cytosolic portion which is
usually more abundant. So far no tools have been developed to
overcome this difficulty and the use of confocal microscopy is usu-
ally not sufficient when one wants to ascertain the localization of a
minor organellar pool of a cytosolic aaRS. Moreover, like for any
other protein putatively organellar, it is currently very difficult to
distinguish between a lumenal localization of an aaRS and a
peripheral localization of the protein on the cytosolic side of the
organelle. Being able to make these distinctions is extremely
important to be able to study the nonconventional roles of these
multi-localized aaRSs and identify the cellular processes to which
the organellar pools of these cytosolic aaRSs participate. Also, the
possibility that several cytosolic aaRSs could be peripherally asso-
ciated to membrane compartments other than the mitochondria
and the nucleus by interacting either with membrane proteins or
directly to lipids has been overlooked so far. For all these reasons,
one still has to turn to the isolation of membranes and afterwards
to organelle purification to be able to ascertain the relocation
inside a given compartment of a fraction of a cytosolic aaRS (sum-
marized in Table 1).
Another difficulty to overcome when working with dual-
localized aaRSs is that the cytosolic pool of these proteins is always
essential for viability, rendering the study of the functions of the
organellar pools of the same aaRS very difficult. In this respect,
yeast is a very convenient model especially when one wants to
analyze the mitochondrial activity of a cytosolic aaRSs. Since these
organelles are only essential for the respiratory metabolism and
not when yeast is fermenting, mutations of the cytosolic aaRS gene
that lead to only a respiratory deficiency (fermentative growth is
unaffected) are targeting residues essential for the mitochondrialactivity of the dual-localized aaRS without affecting its cytosolic
role. This simple phenotypic screen was successfully used to iden-
tify the cryptic and nonconventional MTS of yeast cytosolic GluRS
which participates to the mitochondrial transamidation pathway
upon mitochondrial import [28]. It was also used to show that
mitochondrial forms of His-, Val- and GlyRSs are generated
through an alternative translational start [13,31,32].
If confirming that a pool of a cytosolic aaRS can relocate inside
an organelle is difficult with the current technologies, identifying
the import signals to study the dynamics of these proteins is even
more arduous. Import signal predictors still have a low consensual
predictive accuracy for these dual-localized aaRSs, mainly because
they often contain nonconventional import signals. Identifying the
organellar roles of dual-localized aaRSs will necessitate the reinter-
pretation of previous yeast mutant screens as well as establishing
new mutant screens. In humans, the systematic sequencing of
genes encoding cytosolic aaRSs of patients with mitochondrial-
related diseases and in depth analysis of the localization, protein
interactants and activity of the mutant aaRS is essential for identi-
fying the organellar functions of dual-localized aaRSs. By doing so,
it was recently shown that the mutation in the cytosolic GlyRS
gene that causes type 2D Charcot-Marie-Tooth disease changes
the protein binding activity of GlyRS that interferes with a signal-
ing pathway essential for motor neuron survival [83].
These findings also raise many questions, the most important
being how cells regulate the distribution of multi-compartmental
cytosolic aaRS between the cytosol and the different organelles.
One mechanism by which cells manage the subcellular distribution
of the various pools of a cytosolic aaRS is by forming the MSCs and
triggering release of each cytosolically-anchored aaRS by post-
translational modification of the aaRS. Since so far, a maximum
of 9 cytosolic aaRSs were found participating to MSCs, there are
probably others posttranslational modifications, or other mecha-
nisms that participate in regulating the dynamic compartmental-
ization of the remaining 11 potentially multi-localized aaRSs.
Another important issue concerning the dynamical relocalization
of these aaRSs is whether a portion of an existing pool is redis-
tributed or a fraction of the neosynthesized proteins will specifi-
cally be deviated on demand towards the organelle? Finally,
while in this review we focused on the relocalization of cytosolic
aaRSs within the cell, it has to be noted that several human aaRSs
can be secreted in the extracellular medium where they also
accomplish nonconventional functions [84,85].Acknowledgements
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